Vygenerované: 10.03.2026 07:17:49
Súhrn: Advanced practice clinicians (APCs) appear to be prescribing specialty dermatology medications at a faster rate of growth than physicians, a small new study showed The researchers recently published their findings in a letter in JAMA Dermatology “Although everybody is prescribing more, the growth rate has been faster for APCs,” Kong, who is pursuing an MD degree at the Harvard-MIT Health Sciences and Technology program, told Medscape Medical News.
Doplnenie: Overall spending growth on specialty medications, defined as biologic therapies, was higher for dermatologists than for APCs.
Súhrn: - Home - Medical news & Guidelines - Anesthesiology - Cardiology and CTVS - Critical Care - Dentistry - Dermatology - Diabetes and Endocrinology - ENT - Gastroenterology - Medicine - Nephrology - Neurology - Obstretics-Gynaecology - Oncology - Ophthalmology - Orthopaedics - Pediatrics-Neonatology - Psychiatry - Pulmonology - Radiology - Surgery - Urology - Laboratory Medicine - Diet - Nursing - Paramedical - Physiotherapy - Health news - Fact Check - Bone Health Fact Check - Brain Health Fact Check - Cancer Related Fact Check - Child Care Fact Check - Dental and oral health fact check - Diabetes and metabolic health fact check - Diet and Nutrition Fact Check - Eye and ENT Care Fact Check - Fitness fact check - Gut health fact check - Heart health fact check - Kidney health fact check - Medical education fact check - Men's health fact check - Respiratory fact check - Skin and hair care fact check - Vaccine and Immunization fact check - Women's health fact check - AYUSH - State News - Andaman and Nicobar Islands - Andhra Pradesh - Arunachal Pradesh - Assam - Bihar - Chandigarh - Chattisgarh - Dadra and Nagar Haveli - Daman and Diu - Delhi - Goa - Gujarat - Haryana - Himachal Pradesh - Jammu & Kashmir - Jharkhand - Karnataka - Kerala - Ladakh - Lakshadweep - Madhya Pradesh - Maharashtra - Manipur - Meghalaya - Mizoram - Nagaland - Odisha - Puducherry - Punjab - Rajasthan - Sikkim - Tamil Nadu - Telangana - Tripura - Uttar Pradesh - Uttrakhand - West Bengal - Medical Education - Industry KIMS Hospitals expands in Bengaluru with two super-specialty facilities Bengaluru: Two new super-speciality hospitals have been launched in Bengaluru by Krishna Institute of Medical Sciences (KIMS Hospitals), located in Mahadevapura and Electronic City The Mahadevapura unit has over 450 beds, while the Electronic City facility has 350 beds, strengthening the healthcare infrastructure across the city Both hospitals are equipped with 30 state-of-the-art operation theatres and more than 170 outpatient consultation rooms (OPDs) to provide comprehensive healthcare services.
Doplnenie: Also Read:Thoothukudi 100-bed ESIC Hospital to open by March 2026 The facilities include over 25 super-speciality centres and Centres of Excellence, covering disciplines such as Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management.
Súhrn: - Home - Medical news & Guidelines - Anesthesiology - Cardiology and CTVS - Critical Care - Dentistry - Dermatology - Diabetes and Endocrinology - ENT - Gastroenterology - Medicine - Nephrology - Neurology - Obstretics-Gynaecology - Oncology - Ophthalmology - Orthopaedics - Pediatrics-Neonatology - Psychiatry - Pulmonology - Radiology - Surgery - Urology - Laboratory Medicine - Diet - Nursing - Paramedical - Physiotherapy - Health news - Fact Check - Bone Health Fact Check - Brain Health Fact Check - Cancer Related Fact Check - Child Care Fact Check - Dental and oral health fact check - Diabetes and metabolic health fact check - Diet and Nutrition Fact Check - Eye and ENT Care Fact Check - Fitness fact check - Gut health fact check - Heart health fact check - Kidney health fact check - Medical education fact check - Men's health fact check - Respiratory fact check - Skin and hair care fact check - Vaccine and Immunization fact check - Women's health fact check - AYUSH - State News - Andaman and Nicobar Islands - Andhra Pradesh - Arunachal Pradesh - Assam - Bihar - Chandigarh - Chattisgarh - Dadra and Nagar Haveli - Daman and Diu - Delhi - Goa - Gujarat - Haryana - Himachal Pradesh - Jammu & Kashmir - Jharkhand - Karnataka - Kerala - Ladakh - Lakshadweep - Madhya Pradesh - Maharashtra - Manipur - Meghalaya - Mizoram - Nagaland - Odisha - Puducherry - Punjab - Rajasthan - Sikkim - Tamil Nadu - Telangana - Tripura - Uttar Pradesh - Uttrakhand - West Bengal - Medical Education - Industry Haemoglobin Systolic Pressure Index Better Predicts CV Risk Than HbA1c or SBP Alone: Study Researchers have found in a new study that the Haemoglobin-Systolic Pressure Index (HSI), combining HbA1c and systolic blood pressure, was consistently associated with incident cardiovascular disease across three international cohorts Hypertension and diabetes are major drivers of cardiovascular disease (CVD), and their coexistence confers excess risk This study aimed to develop a hemoglobin A1c (HbA1c)-systolic blood pressure (SBP) index (HSI) to simultaneously capture glucose and blood pressure status and investigate the associations of baseline and cumulative HSI with incident cardiovascular disease.
Doplnenie: This study aimed to develop a hemoglobin A1c (HbA1c)-systolic blood pressure (SBP) index (HSI) to simultaneously capture glucose and blood pressure status and investigate the associations of baseline and cumulative HSI with incident cardiovascular disease.
Súhrn: TOPLINE: In an interim analysis of a phase 2/3 study, neoadjuvant therapy with gemcitabine-oxaliplatin, lenvatinib, and toripalimab (GOLP regimen) more than doubled the median event-free survival time vs surgery followed by adjuvant capecitabine in patients with resectable high-risk intrahepatic cholangiocarcinoma Because randomized data are lacking, guidelines do not recommend neoadjuvant therapy The GOLP regimen — gemcitabine-oxaliplatin plus lenvatinib and an anti-PD-1 antibody — has shown promising activity as both first-line and conversion therapy, providing a rationale to evaluate it in the neoadjuvant setting in this population.
Doplnenie: Because randomized data are lacking, guidelines do not recommend neoadjuvant therapy.